Latest Breaking News On - Holm keller - Page 3 : vimarsana.com

Strong backing for vaccine production for Africa

Banque européenne et BiondVax (Israël). Vaccin contre la grippe.

Mini-antibodies efficiently block SARS-CoV-2 virus

Mini-antibodies efficiently block SARS-CoV-2 virus Göttingen researchers have developed mini-antibodies that efficiently block the coronavirus SARS-CoV-2 and its dangerous new variants. These so-called nanobodies bind and neutralize the virus up to 1000 times better than previously developed mini-antibodies. In addition, the scientists optimized their mini-antibodies for stability and resistance to extreme heat. This unique combination makes them promising agents to treat COVID-19. Since nanobodies can be produced at low costs in large quantities, they could meet the global demand for COVID-19 therapeutics. The new nanobodies are currently in preparation for clinical trials. Antibodies help our immune system to fend off pathogens. For example, the molecules attach to viruses and neutralize them so that they can no longer infect cells. Antibodies can also be produced industrially and administered to acutely ill patients. They then act like drugs, relieving symptoms and shortening recovery from the disease. This is established practice for treating hepatitis B and rabies. Antibodies are also used for treating COVID-19 patients. However, producing these molecules on an industrial scale is too complex and expensive to meet worldwide demand. Nanobodies could solve this problem.

Nanobodies stop Sars-CoV-2 and its new variants

WHO - World Health Organization (via Public) / WHO Director-General's opening remarks at the mRNA Malaria Vaccine event

Private and Public Sector Join Forces Under the Umbrella of the kENUP Foundation: BioNTech Announces Project to Develop the First mRNA-Based Prophylactic Malaria vaccine, and the set-up of Manufacturing Infrastructures in Africa

Sanaria researchers make progress in the development of highly protective malaria vaccine

Sanaria researchers make progress in the development of highly protective malaria vaccine Researchers from Sanaria ® Inc. and the National Institutes of Health (NIH) are making progress in the development of highly protective malaria vaccines. In an article published today in Nature, Sanaria's PfSPZ-CVac (CQ) vaccine is reported as being safe and protecting 100% of six subjects against a variant malaria parasite three months after their last dose in the company's Phase 1 safety and efficacy trial. This is the first time complete protection against a variant malaria parasite has ever been achieved that long after vaccine administration. The variant parasite used in the trial is a Brazilian malaria parasite genetically more variant from the African parasites in the vaccine than 700 malaria parasites from Africa. Protection was achieved at a dose that is 20% of the company's first-generation malaria vaccine dosage.

Sanaria Vaccine trial results demonstrate unprecedented progress in worldwide battle against variant malaria parasites

Sanaria vaccine results show unprecedented progress in battle against variant malaria

A vaccine that serves all of humanity – not private profit

IN households across the country, there are huge sighs of relief as family members and friends get the coronavirus vaccine.  The vaccine is a key weapon in the fight against the virus, to help stop the deaths and get life back to something more normal. At the time of writing, the NHS has administered 15 million jabs, an impressive feat and one that contrasts with how outsourcing giants botched the test and trace system, contributing to the virus spiralling out of control and leading to Britain having one of the world’s highest death tolls. But this kind of vaccine rollout isn’t happening everywhere. Some estimates show that in the world’s poorest countries nine out of 10 people won’t have been vaccinated this year.